NIR-PIT utilizing trastuzumab-IR700 has been effective in xenograft models with a human breast cancer cell line, in pleural dissemination models by HER2 expressing NSCLC cells, in esophageal carcinoma cell lines in vitro, and in subcutaneous tumor models and disseminated peritoneal models with several ovarian cancer cell lines [1,64,65,66]. Here, ERBB2 is linked to breast cancer.